# US 2015/0106962 A1 · Miniature swine transgenic for one or more coagulation factors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0106962 A1
- Document ID: US20150106962A1
- Status: Published application
- Kind: A1
- Application number: 14/403,764
- Filed: 2013-06-11
- Published: 2015-04-16
- Earliest claimed: 2012-06-12
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: David H. Sachs; Martin Hertl
- Web page: https://patentgrep.com/patent/US20150106962A1

## CPC

- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C12N 5/067: {Hepatocytes}
- C12N 9/1048: {Glycosyltransferases (2.4)}
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- C12N 9/6432: {Coagulation factor Xa (3.4.21.6)}
- C12N 9/6437: {Coagulation factor VIIa (3.4.21.21)}
- C12N 9/6451: {Coagulation factor XIIa (3.4.21.38)}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/203: Animal model comprising inducible/conditional expression system, e.g. hormones, tet
- A01K 2227/108: Swine
- A01K 2267/025: Animal producing cells or organs for transplantation
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Transgenic swine that express human coagulation factors, e.g., human coagulation factor VII, and/or one or more of human coagulation factors II, X and XII, and do not express the corresponding porcine coagulation factor or factors, as well as cells, tissues and organs derived therefrom, and their use in transplantation procedures.

## Claims

### Claim 1

A transgenic swine in which a human coagulation factor is expressed in at least one organ or tissue type.

### Claim 2 (depends on 1)

The transgenic swine of claim 1, in which the human coagulation factor is selected from the group consisting of human coagulation factor VII, II, X and XII.

### Claim 3 (depends on 1)

The transgenic swine of claim 1, in which the human coagulation factor is expressed in the liver of the swine.

### Claim 4 (depends on 1)

The transgenic swine of claim 1, in which the normal expression of a porcine coagulation factor is prevented in at least one organ or tissue type.

### Claim 5 (depends on 4)

The transgenic swine of claim 4, which has been made to produce a nucleic acid sequence that binds to and prevents the translation of mRNA coding for a porcine coagulation factor in said swine.

### Claim 6 (depends on 4)

The transgenic swine of claim 4, in which the sequence for the porcine coagulation factor has been replaced by a sequence encoding a human coagulation factor.

### Claim 7 (depends on 1)

The transgenic swine of claim 1, whose genome had been modified to include a construct comprising a DNA encoding a human coagulation factor operably linked to a promoter therefore.

### Claim 8 (depends on 7)

The transgenic swine of claim 7, wherein the promoter is a strong non-tissue specific constitutive or regulatable promoter, or a strong tissue specific constitutive or regulatable promoter.

### Claim 9 (depends on 7)

The transgenic swine of claim 7, wherein the promoter is from the porcine coagulation factor.

### Claim 10 (depends on 1)

The transgenic swine of claim 1, which lacks expression of porcine alpha(1, 3)galactosyltransferase.

### Claim 11 (depends on 1)

The transgenic swine of claim 1, which was grown from a porcine oocyte whose pronuclear material has been removed and into which has been introduced a pluripotent porcine embryonic stem cell that contains a DNA encoding a human coagulation factor operably, and optionally lacks a DNA encoding a functional porcine coagulation factor.

### Claim 12 (depends on 1)

The transgenic swine of claim 1, grown from a porcine zygote which has been modified by homologous recombination of a human coagulation factor in an isogenic DNA targeting vector, preferably into the corresponding porcine coagulation factor chromosomal locus.

### Claim 13 (depends on 1)

The transgenic swine of claim 1, wherein the isogenic DNA targeting vector comprises a selectable marker gene.

### Claim 14

Porcine cells, in vitro, said cells expressing at least one human coagulation factor.

### Claim 15 (depends on 14)

The cells of claim 14, wherein the human coagulation factor is selected from the group consisting of human coagulation factor VII, and/or one or more of human coagulation factors II, X and XII.

### Claim 16 (depends on 14)

The cells of claim 14, which are liver cells.
